Business Wire

MA-NETSCOUT-SYSTEMS

22.3.2022 11:02:06 CET | Business Wire | Press release

Share
Bad Actors Innovate, Extort and Launch 9.7M DDoS Attacks in 2021 According to the Latest NETSCOUT Threat Intelligence Report

NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report . During the second half of 2021, cybercriminals launched approximately 4.4 million Distributed Denial of Service (DDoS) attacks, bringing the total number of DDoS attacks in 2021 to 9.75 million. These attacks represent a 3% decrease from the record number set during the height of the pandemic but continue at a pace that's 14% above pre-pandemic levels.

The report details how the second half of 2021 established high-powered botnet armies and rebalanced the scales between volumetric and direct-path (non-spoofed) attacks, creating more sophisticated operating procedures for attackers and adding new tactics, techniques, and methods to their arsenals.

“While it may be tempting to look at the decrease in overall attacks as threat actors scaling back their efforts, we saw significantly higher activity compared to pre-pandemic levels,” said Richard Hummel, threat intelligence lead, NETSCOUT. “The reality is that attackers are constantly innovating and adapting new techniques, including the use of server-class botnets, DDoS-for-Hire services, and increased used direct-path attacks that continually perpetuate the advancement of the threat landscape.”

Other key findings from the NETSCOUT 2H2021 Threat Intelligence Report include:

  • DDoS Extortion and Ransomware Operations are on the rise. Three high-profile DDoS extortion campaigns simultaneously operating is a new high. Ransomware gangs including Avaddon, REvil, BlackCat, AvosLocker, and Suncrypt were observed using DDoS to extort victims. Because of their success, ransomware groups have DDoS extortion operators masquerading as affiliates like the recent REvil DDoS Extortion campaign.
  • VOIP Services were Targets of DDoS Extortion. Worldwide DDoS extortion attack campaigns from the REvil copycat were waged against several VOIP services providers. One VOIP service provider reported $9M-$12M in revenue loss due to DDoS attacks.
  • DDoS-for-Hire services made attacks easy to launch. NETSCOUT examined 19 DDoS-for-Hire services and their capabilities that eliminate the technical requirements and cost of launching massive DDoS attacks. When combined, they offer more than 200 different attack types.
  • APAC attacks increased by 7% as other regions subsided . Amid ongoing geopolitical tensions in China, Hong Kong, and Taiwan, the Asia-Pacific region saw the most significant increase in attacks year over year compared to other regions.
  • Server-class botnet armies arrived. Cybercriminals have not only increased the number of Internet-of-Things (IoT) botnets but have also conscripted high-powered servers and high-capacity network devices, as seen with the GitMirai, Meris, and Dvinis botnets.
  • Direct-path attacks are gaining in popularity . Adversaries inundated organizations with TCP- and UDP-based floods, otherwise known as direct-path or non-spoofed attacks. Meanwhile, a decrease in some amplification attacks drove down the number of total attacks.
  • Attackers targeted select industries . Those hardest hit include software publishers (606% increase), insurance agencies and brokers (257% increase), computer manufacturers (162% increase), and colleges, universities, and professional schools (102% increase)
  • The fastest DDoS attack recorded a 107% year-over-year increase. Using DNS, DNS amplification, ICMP, TCP, ACK, TCP RST, and TCP SYN vectors, the multi-vector attack against a target in Russia recorded 453 Mpps.

NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data captured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with insights from NETSCOUT's ATLAS Security Engineering & Response Team.

The visibility and insights compiled from the global DDOS attack data, which is represented in the Threat Intelligence Report and can be seen in the Omnis Threat Horizon portal, fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security portfolio to detect and block threat activity for enterprises and service providers worldwide.

Visit our interactive website for more information on NETSCOUT's semi-annual Threat Intelligence Report. You can also find us on Facebook , LinkedIn , and Twitter for threat updates and the latest trends and insights.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Omnis® Cyber Intelligence delivers the fastest and most scalable network security solution available on the market. NETSCOUT nGenius® service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor® Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.

©2022 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

Social Media:

https://www.facebook.com/NETSCOUTinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye